Specialized histopathological second opinion of advanced ovarian cancer: Experiences with collectives from prospective randomized phase III studies;Spezialisierte histopathologische Zweitbegutachtung fortgeschrittener Ovarialkarzinome: Erfahrungen an Kollektiven aus prospektiv randomisierten Phase-III-Studien

Pathologe

Volumn 35, Issue 4, 2014, Pages 355-360

  Kommoss, S ^a   Pfisterer, J ^b   Du Bois, A ^c   Schmidt, D ^d   Kommoss, F ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c KLINIKEN ESSEN MITTE   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

Borderline tumor; Chemotherapy trial; Consultation pathology; Diagnostic discrepancies; Metastasis

Indexed keywords

ADENOCARCINOMA, CLEAR CELL; CANCER STAGING; CARCINOMA, ENDOMETRIOID; CLINICAL TRIAL; COLON TUMOR; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE COURSE; FEMALE; GERMANY; HUMAN; MULTICENTER STUDY; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PATIENT REFERRAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY;

ADENOCARCINOMA, CLEAR CELL; CARCINOMA, ENDOMETRIOID; COLONIC NEOPLASMS; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PATIENT SELECTION; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION;

EID: 84905384178     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-014-1911-5     Document Type: Article

References (15)

1. Howlader N, Noone A, Krapcho M et al (Hrsg) (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012
2. Trimble CL, Kosary C, Trimble EL (2002) Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 86(1):34-37
3. Tyler CW Jr et al (1991) The diagnosis of ovarian cancer by pathologists: how often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 164(1 Pt 1):65-70
4. Sengupta PS et al (2000) Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer 82(4):760-762
5. Leitao MM Jr et al (2004) Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol 28(2):147-159
6. Young RH (2006) From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol 13(5):205-227
7. Young RH (2007) From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 14(3):149-177
8. Tavassoli FA, Devilee P (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon
9. Kommoss S et al (2013) Specialized pathology review in patients with ovarian cancer: results from a prospective study. Int J Gynecol Cancer 23(8):1376-1382
10. Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496
11. Soslow R (2011) Common diagnostic discrepancies. In: Soslow RA, Tornos C (Hrsg) Diagnostic pathology of ovarian tumors. Springer, Berlin Heidelberg New York, S 11-14
12. Kommoss S, PfistererJ, Diebold J et al (2013) Second opinion pathology in clinical trials of ovarian carcinomas: the use of a new internet-based pathology platform makes rapid case review prior to patient enrolment possible. Poster presentation, 97. Jahrestagung der Deutschen Gesellschaft für Pathologie 2013. Pathologe, Heidelberg, S 6-164
13. Kommoss S et al (2014) Making Better Use of Resources and Optimizing Quality of Care for Ovarian Cancer Patients Using Internet-Based Second Opinion Pathology - Standardized in an Ovarian Cancer Network. United States and Canadian Academy of Pathology, 2014 Annual Meeting, San Diego, USA. Modern Pathol 27(Suppl 2):290A
14. Rocken C et al (2013) Participation and support of clinical studies and other scientific investigations. Statement of the German Society for Pathology. Pathologe 34(5):466-475
15. Kommoss F, Kommoss S, Schmidt D et al (2008) Central pathology review. Inclusion criterion for clinical studies of ovarian carcinomas? Pathologe 29(Suppl 2):157-159